Skip to content
Screener

Syndax Pharmaceuticals SNDX Q1 2026 earnings

Reported April 30, 2026 · After market close

Revenue$64.9MMiss by $4.9M
EPS-$0.48Beat by $0.11
Revenue estimate$69.8M
EPS estimate-$0.59

Next report

Nov 2, 2026 (in a month)
Revenue estimate$82.8M
EPS estimate-$0.51

Financials

Q1 2026

Income statement

See full
Revenue$64.9M+224%
Operating income-$34.2M+59.2%
Net income-$42.7M+49.7%
EPS (diluted)-$0.48+51.0%

Balance sheet

See full
Cash & equivalents$130.9M-15.0%
Total debt$350.5M+4.2%
Total equity$41.6M-80.6%
Total assets$472.7M-26.2%

Cash flow

See full
Operating cash flow-$50.3M+47.1%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$2.06B+95.0%
Enterprise value$2.28B+84.0%
P/S9.5×-14.7×

Profitability

See full
Operating margin-102.8%-47.8pp
Net margin-111.9%-51.5pp

Returns & leverage

See full
Return on equity-189.5%-8,509pp
Debt / equity8.4×+6.9×
Current ratio5.5×-0.3×

FAQ

When did Syndax Pharmaceuticals report Q1 2026 earnings?
Syndax Pharmaceuticals (SNDX) reported Q1 2026 earnings on April 30, 2026 after market close.
What were Syndax Pharmaceuticals's Q1 2026 revenue and EPS?
Syndax Pharmaceuticals reported revenue of $64.9M and eps of $-0.48 for Q1 2026.
Did Syndax Pharmaceuticals beat estimates in Q1 2026?
Revenue missed the consensus estimate of $69.8M by $4.9M. EPS beat the consensus estimate of $-0.59 by $0.11.
How did Syndax Pharmaceuticals's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 223.6% from $20.0M a year earlier and eps grew 51.0% from $-0.98.
Where can I find Syndax Pharmaceuticals's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-197124) and the 10-Q periodic report (0001193125-26-197154) directly on SEC EDGAR. The filing index links above go to sec.gov.